The association of ecg TV1>TV6 phenomenon as electrophysiological sign of metabolic myocardial disorders with risk factors for ischemic heart disease in the population of 25–44 years

 The aim of the study was to study the associations of electrophysiological signs of metabolic disorders the myocardium (ECG phenomenon TV1>TV6 and components of the ECG of the of left ventricular hypertrophy phenomenon) with some lipid and non-lipid risk factors in an urban population of 25–44 years.

Material and methods. A population survey of a random sample of the
population aged 25–44 years (1439 people, 656 men, 783 women) in  Novosibirsk was conducted. Blood concentrations of total cholesterol, high (HDL-C) and low density lipoprotein cholesterol (LDL-C), and triglycerides were measured. Systolic and diastolic blood pressure, body mass index, waist circumference, presence of arterial hypertension, smoking status were  evaluated. The following ECG markers were analyzed: ECG phenomenon TV1>TV6 (the amplitude of T in V1 exceeds the amplitude of T in V6), components of the ECG of the of left ventricular hypertrophy phenomenon.

Results. ECG phenomenon TV1>TV6 was detected in 0.8 % of people (1.4 % of men, 0.2 % of women). In the general population among people with ECG phenomenon TV1>TV6, persons with triglyceride levels >150 mg/dl, with an increased body mass index/waist circumference, with arterial hypertension are 3.0, 2.0, 2.3 and 3.5 times more, respectively, than among people without ECG phenomenon TV1>TV6. Among men with ECG phenomenon TV1>TV6, persons with elevated triglyceride levels, with an increased body mass index/waist circumference, with arterial hypertension are 2.2, 1.5, 2.5 and 2.8 times more, respectively, than among men without ECG phenomenon TV1>TV6. The components of the ECG of the of left ventricular hypertrophy  phenomenon were found in 1.4 % of people (2.1 % of men, 0.9 % of women). In the general population, among people with elevated triglyceride levels, with arterial hypertension, as well as in smokers – individuals with signs of left ventricular hypertrophy are 2.3, 2.1 and 1.7 times more,  respectively, than without them. Among men with elevated blood levels of LDL-C, non-HDL-C, as well as smokers-individuals with components of the ECG of the of left ventricular hypertrophy phenomenon are 1.4, 1.4 and 1.6 times more, respectively.

Conclusions. ECG phenomenon TV1>TV6 and components of the ECG of
the of left ventricular hypertrophy phenomenon are associated with lipid  and non-lipid risk factors for cardiovascular diseases, which indicates a potentiating effect of metabolic disorders in the body not only on the development of risk factors for cardiovascular diseases, but also metabolic  disorders of the myocardium. 

1. Boytsov S.A., Shalnova S.A., Deev A.D. Cardiovascular mortality in the Russian Federation and possible mechanisms of its changes. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018; 118 (8): 98–103. (In Russ.) doi: 10.17116/jnevro201811808198

2. Shalnova S.A., Oganov R.G., Deev A.D., Imaeva A.E., Lukyanov М.М., Artamonova G.V., Gatagonova Т.М., Grinshtein Yu.I., Duplyakov D.V., Efanov А.Yu., Zhernakova Yu.V., Ilyin V.A., Libis R.A., Minakov A.V., Nevzorova V.A., Nedogoda S.V., Romanchuk S.A., Rotar O.P., Trubacheva I.A., Shlyakhto E.V., Boytsov S.A., Balanova Yu.A., Muromtseva G.A., Evstifeeva S.E., Kapustina A.V., Mamedov M.N., Gutnova S.K., Toguzova Z.A., Tolparov G.V., Kulakova N.V., Shestakova N.V., Mokshina M.V., Rodionova L.V., Chumachek E.V., Ledyaeva A.A., Kasimov R.A., Shabunova A.A., Leonidova G.V., Kalashnikov K.N., Kalachikova O.N., Rossoshansky A.I., Kondakova N.A., Popov A.V., Ustinova K.A., Furmenko G.I., Babenko N.I., Azarin O.G., Bondartsov L.V., Khvostikova A.E., Nazarova O.A., Belova O.A., Shutemova E.A., Petrova M.M., Danilova L.K., Evsyukov A.A., Topolskaya N.V., Shabalin V.V., Aristov A.I., Ruf R.R., Kosinova A.A., Shmatova E.N., Kaskaeva D.S., Basyrova I.R., Kondratenko V.Yu., Lopina E.A., Safonova D.V., Gudkova S.A., Cherepanova N.A., Karpov R.S., Kaveshnikov V.S., Serebryakova V.N., Medvedeva I.V., Shava V.P., Shalaev S.V., Barbarash O.L., Skripchenko A.E., Indukaeva E.V., Mulerova T.A., Maksimov S.A., Cherkass N.V., Tabakaev M.V., Danilchenko Ya.V. Comorbidities of ischemic heart disease with other non-communicable diseases in adult population: age and risk factors association. Cardiovascular. Therapy and Prevention. 2015; 14 (4): 44–51. (In Russ.) doi: 10.15829/1728-8800-2015-4-44-51

3. Clinical electrocardiology. In: Functional diagnostics: national guidelines. Eds: N.F. Beresten, V.A. Sandrikova, S.I. Fedorova. M.: GEOTAR-Media, 2019. P. 47–207. (In Russ.)

4. Ageeva L.I., Aleksandrova G.A., Zajchenko N.M., Kirillova G.N., Leonov S.A., Ogryzko E.V., Titova I.A., Har’kova T.L., Chumarina V.ZH., Shubochkina E.M.

5. Witteles R.M., Fowler M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. Coll. Cardiol., 2008; 51 (2): 93–102. doi: 10.1016/j.jacc.2007.10.021

6. Timoshenko N.A., Ragino Yu.I., Voevoda M.I. Metabolic cardiomyopathy. Current state of problem. Ateroscleroz, 2013; 9 (1): 65–77. (In Russ.)

7. Muromtseva G.A., Deev A.D., Konstantinov V.V., Shalnova A.A., Boytsov S.A. The prevalence of electrocardiographic indicators among men and women of older ages in the Russian Federation. Rational Pharmacotherapy in Cardiology, 2016; 12 (6): 711–717. (In Russ.) doi: 10.20996/1819-6446-2016-12-6-711-717

8. Andreenko E.Yu., Yavelov I.S., Loukianov M.M., Vernohaeva A.N., Drapkina O.M., Boytsov S.A. Ischemic Heart Disease in Subjects of Young Age: Current State of the Problem. Prevalence and CardioVascular Risk Factors. Kardiologiia, 2018; 58 (10): 53–58. (In Russ.) doi: 10.18087/cardio.2018.10.10184

9. Coffman E., Richmond-Bryant J. Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study. Popul Health Metr., 2015; 13: 7. doi: 10.1186/s12963-015-0041-5

10. Krikunova O.V., Vasyuk Yu.A., Viskov R.V., Krikunov P.V., Ivanova S.V. Significance of troponin tests for differential diagnosis and prediction in heart failure. Russian Heart Failure Journal, 2015; 16 (4): 254–260. (In Russ.) doi: 10.18087/rhfj.2015.4.2122

11. Bova A.A. Cardiomyopathy: state of the problem. Voennaya meditsina, 2011; 2: 18–24. (In Russ.)

12. Timoshenko N.A., Ragino Yu.I., Chernjavskyi A.M., Tcimbal S.Yu., Scherbakova L.V., Voevoda M.I. Association of electrocardiographic markers of metabolic cardiomyopathy with long-term results of myocardial revascularization in men with coronary atherosclerosis. Russian Journal of Cardiology, 2014; (6): 57–31. (In Russ.) doi: 10.15829/1560-4071-2014-6-57-31

13. Borja M.S., Hammerson B., Tang C., Savinova O.V., Shearer G.C., Oda M.N. Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease. PLoS One, 2017; 12 (8): e0182217. doi: 10.1371/journal.pone.0182217

14. Lim Y., Yoo S., Lee S.A., Chin S.O., Heo D., Moon J.C., Moon S., Boo K., Kim S.T., Seo H.M., Jwa H., Koh G. Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes. Endocrinol. Metab. (Seoul), 2015; 30 (2): 208–215. doi: 10.3803/EnM.2015.30.2.208

15. Roytman A.P., Fedorova T.A., Ivanova E.A., Bugrov A.V., Dolgov V.V. The role of metabolism disorders, inflammation, myocardial injury in development chronic heart failure in metabolic syndrome patients. Lab. Service, 2018; 7 (4): 5–10. (In Russ.) doi: 10.17116/labs201870415

16. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D.L., Coca A., de Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S.E., Kreutz R., Laurent S., Lip G.Y.H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R.E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I.; Authors/Task Force Members: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J. Hypertens, 2018; 36 (10): 1953–2041. doi: 10.1097/HJH.0000000000001940

17. Rovio S.P., Pahkala K., Nevalainen J., Juonala M., Salo P., Kähönen M., Hutri-Kähönen N., Lehtimäki T., Jokinen E., Laitinen T., Taittonen L., Tossavainen P., Viikari J.S.A., Rinne J.O., Raitakari O.T. Cardiovascular Risk Factors From Childhood and Midlife Cognitive Performance: The Young Finns Study. J. Am. Coll. Cardiol., 2017; 69 (18): 2279–2289. doi: 10.1016/j.jacc.2017.02.060

18. Gottesman R.F., Albert M.S., Alonso A., Coker L.H., Coresh J., Davis S.M., Deal J.A., McKhann G.M., Mosley T.H., Sharrett A.R., Schneider A.L.C., Windham B.G., Wruck L.M., Knopman D.S. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort. JAMA Neurol., 2017; 74 (10): 1246–1254. doi: 10.1001/jamaneurol.2017.1658

19. Lip G.Y.H., Coca A., Kahan T., Boriani G., Manolis A.S., Olsen M.H., Oto A., Potpara T.S., Steffel J., Marín F., de Oliveira Figueiredo M.J., de Simone G., Tzou W.S., En Chiang C., Williams B. Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaciуn Cardнaca y Electrofisiologнa (SOLEACE). Eur. Heart. J. Cardiovasc. Pharmacother., 2017; 3 (4): 235–250. doi: 10.1093/ehjcvp/pvx019

20. Chazova I.E., Zhernakova Yu.V. on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension, 2019; 16 (1): 6–31. (In Russ.) doi: 10.26442/2075082X.2019.1.190179

21. Ryabikov A.N. Structural changes in the arterial wall and myocardium in the population according to ultrasound data: methodological aspects, determinants and prognostic significance. PhD dissertation. Institute of Internal and Preventive Medicine – Branch of IC&G SB RAS, Novosibirsk, 2006: 265 p. (In Russ.)

22. Malyutina S.K., Ryabikov A.N., Shakhmatov S.G., Gafarov V.V., Verevkin E.G., Nikitin Yu.P. Arterial hypertension and target organs damage: prognostic significance of myocardium hypertrophy in Siberian population. The Bulletin of Siberian Branch of Russian Academy of Medical Sciences, 2011; 31 (5): 53–58. (In Russ.)

23. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Villevalde S.V., Galyavich A.S., Glezer M.G., Drapkina O.M., Kotovskaya Yu.V., Libis R.A., Lopatin Yu.M., Nedoshivin A.O., Ostroumova O.D., Ratova L.G., Tkacheva O.N., Chazova I.E., Chesnikova A.I., Chumakova G.A. Russian Society of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology/European Society of Arterial Hypertension for the management of arterial hypertension. Rus. J. Cardiol., 2018; (12): 131–142. (In Russ.) doi: 10.15829/1560-4071-2018-12-131-142

24. Salles G.F., Reboldi G., Fagard R.H., Cardoso C.R., Pierdomenico S.D., Verdecchia P., Eguchi K., Kario K., Hoshide S., Polonia J., de la Sierra A., Hermida R.C., Dolan E., O’Brien E., Roush G.C.; ABCH Investigators. Prognostic Effect of the Nocturnal Blood Pressure Fall in Hypertensive Patients: The Ambulatory Blood Pressure Collaboration in Patients With Hypertension (ABC-H) Meta-Analysis. Hypertension, 2016; 67 (4): 693–700. doi: 10.1161/HYPERTENSIONAHA.115.06981

25. Pongpanich P., Pitakpaiboonkul P., Takkavatakarn K., Praditpornsilpa K., Eiam-Ong S., Susantitaphong P. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. Int. Urol. Nephrol, 2018; 50 (12): 2261–2278. doi: 10.1007/s11255-018-1991-x

26. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J. Hypertens., 2017; 35 (11): 2150–2160. doi: 10.1097/HJH.0000000000001547

27. Lehtonen A.O., Puukka P., Varis J., Porthan K., Tikkanen J.T., Nieminen M.S., Huikuri H.V., Anttila I., Nikus K., Kähönen M., Jula A., Niiranen T.J. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J. Hypertens., 2016; 34 (5): 959–966. doi: 10.1097/HJH.0000000000000882

28. Shi Y., Zhou W., Liu X., Ping Z., Li Y.Q., Wang C., Lu J., Mao Z.X., Zhao J., Yin L., Zhang D., Li L. Resting heart rate and the risk of hypertension and heart failure: a dose-response meta-analysis of prospective studies. J. Hypertens., 2018; 36 (5): 995–1004. doi: 10.1097/HJH.0000000000001627

29. Muromtseva G.A., Vilkov V.G., Shalnova S.A., Konstantinov V.V., Deev A.D., Evstifeeva S.E., Balanova Yu.A., Imaeva A.E., Kapustina A.V., Karamnova N.S., Shlyakhto E.V., Boytsov S.A., Nedogoda S.V., Shabunova A.A., Chernykh T.M., Belova O.A., Indukaeva E.V., Grinshteyn Yu.I., Trubacheva I.A., Efanov A.Yu., Astakhova Z.T., Kulakova N.V. The prevalence of wide QRS complex (≥ 110 ms) among the population, depending on sex, age and place of residence. Rus. J. Cardiol., 2020; 25 (6): 3478. (In Russ.) doi: 10.15829/1560-4071-2020-3478

30. Zachrisson K., Herlitz H., Lönn L., Falkenberg M., Eklöf H. Duplex ultrasound for identifying renal artery stenosis: direct criteria re-evaluated. Acta Radiol., 2017; 58 (2): 176–182. doi: 10.1177/0284185116641345

31. Albasri A., O’Sullivan J.W., Roberts N.W., Prinjha S., McManus R.J., Sheppard J.P. A comparison of blood pressure in community pharmacies with ambulatory, home and general practitioner office readings: systematic review and meta-analysis. J. Hypertens., 2017; 35 (10): 1919–1928. doi: 10.1097/HJH.0000000000001443